Strong data re:skin outcomes from VALOR, RCT of brep in dermatomyositis NNT for skin remission ~4 (CDASI-A >14: 43.5% vs 20.8%), itch remission ~5 (itch remission <=1: 43.2% vs 24.1%), & itch improvement ~ 2 (74.0% vs 33.3%) Itch is underappreciated & frustrating; nice data for https://t.co/tJus4RXwod

Weak non-Jo1 antisynthetase abs are unhelpful Out of 171 suspected ASyS pts, weak positives were ALL false positives At highter positivity, more likely to be true disease (PPV ~80% at higher levels) Important cautionary tale when diagnosis ASyS; soft antibodies are highly https://t.co/uwXZ2j79oz

ACR Research Highlights Pediatric Treatment Gaps, Criteria Performance, and Early Promise of CAR T-Cell Therapy New research presented at ACR Convergence 2026 examines pediatric patient’s symptoms and potential therapies that can assist children and adolescents with symptom https://t.co/AZT1bFaoEm

PDE4 inhibitors work for Behcets! Not exactly surprising, but nice to see a consistent signal in this meta analysis of RCTs Over 3 trials & 408 pts, PDE4 improved complete oral-ulcer response (OR 4.4), sustained ulcer-free response (OR 9.24) (3.78-22.59). complete https://t.co/MhsXwK9kW4

Does deucravacitinib work for the spine? Pt w/ axial disease (investigator defined) in POETYK-1 and 2: about ~15% of participants Disparate findings: - POETYK-1: response not sig differrent from PBO - POETYK-2: response sig improved over PBO @RheumNow #ACR26 #Abst1319 https://t.co/RTwxGnOGlf

In case you were in doubt, immune checkpoint inhibitor-induced inflammatory arthritis can persist on, long after the culpable ICI has stopped. n=67 ICI-IA active >3mo post-ICI cessation @UChicago these pts need real care into survivorship @ReidMDMPH ABST1682 #ACR26 @RheumNow https://t.co/7zQJbFwp18

This target trial emulation by Dr. SGarg et al show HCQ blood levels >1150 ng/mL was assoc'd with a 2fold higher risk of retinopathy (HR 2.4) HCQ wgt-based dosing not assoc'd w/ retinopathy (HR 0.81) Supports use of HCQ blood level monitoring @RheumNow #ACR26 Abs1223 https://t.co/RwEunbQ2LK

Risk factors for relapse in IgG4-RD: - high serum IgG4 level at dx - multi-organ disease - high serum IgE - peripheral eosinophilia Can this help us tailor steroid tapers and steroid sparing therapy? @RheumNow #ACR26 https://t.co/QfJJFXFEBV

REGENCY: obinutuzumab led to deep kidney B-cell depletion. In patients without complete clinical renal response, histological activity was 0 at W76 in 10/19 vs 2/24 on PBO. Supports assessment of histo outcomes in LN trials & Obi for long-term kidney health #1823 @Rheumnow #ACR26 https://t.co/wDTS3oLLFy

Ab#1823 #ACR26 @RheumNow REGENCY, Furie OBI in LN: Wk76- OBI complete renal remiss (CRR) 46 v PBO 33% Non-CRR w proteinuria: Fail v damage? OBI - complete histologic remission, depleted B cells Histo remiss 47% v 19% PBO Suggests more impr outcomes in LN beyond endpt CRR #ACRBest https://t.co/qWv1KYxBXT

Pred >40mg daily is probably NOT necessary for IgG4-RD Remission rates do not improve with higher vs medium doses Just more potential for problems #ACR26 @RheumNow https://t.co/MWMiDkfk4r